{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:55:14Z","timestamp":1761461714859,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.coph.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T19:10:50Z","timestamp":1557342650000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Pharmacological development in hidradenitis suppurativa"],"prefix":"10.1016","volume":"46","author":[{"given":"\u0141ukasz","family":"Matusiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor BE","family":"Jemec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek C","family":"Szepietowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2019.04.006_bib0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"23","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.coph.2019.04.006_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000443878","article-title":"The ABC of hidradenitis suppurativa: a validated glossary on how to name lesions","volume":"232","author":"Lipsker","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.coph.2019.04.006_bib0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","article-title":"Hidradenitis suppurativa","volume":"23","author":"Revuz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Suppl. 1","key":"10.1016\/j.coph.2019.04.006_bib0020","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jaad.2015.07.052","article-title":"Hidradenitis suppurativa: epidemiology and scope of the problem","volume":"73","author":"Jemec","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_sbref0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2019.04.006_bib0030","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis suppurativa: advances in diagnosis and treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2019.04.006_sbref0035","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.coph.2019.04.006_bib0040","first-page":"241","article-title":"Current systemic treatment strategies for hidradenitis suppurativa","volume":"5","author":"Ponikowska","year":"2017","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.coph.2019.04.006_bib0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.coph.2019.04.006_bib0050","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1365-2133.2006.07155.x","article-title":"Clindamycin and rifampicin combination therapy for hidradenitis suppurativa","volume":"154","author":"Mendoca","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","article-title":"The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa","volume":"219","author":"Van Der Zee","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.coph.2019.04.006_bib0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jdv.12127","article-title":"Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients","volume":"28","author":"Bettoli","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2019.04.006_bib0065","series-title":"Hidradenitis Suppurativa","first-page":"183","article-title":"Treatment","author":"Jemec","year":"2006"},{"key":"10.1016\/j.coph.2019.04.006_bib0070","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-199243040-00010","article-title":"Acitretin: a review of its pharmacology and therapeutic use","volume":"43","author":"Pilkington","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2019.04.006_bib0075","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjd.12884","article-title":"Acitretin treatment of hidradenitis suppurativa: a prospective series of 17 patients","volume":"171","author":"Matusiak","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0080","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2010.10071.x","article-title":"Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?","volume":"164","author":"Boer","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0085","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2019.04.006_bib0090","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cyto.2017.12.020","article-title":"Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativar","volume":"103","author":"Jimenez-Gallo","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.coph.2019.04.006_bib0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2310\/7750.2012.11144","article-title":"Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy","volume":"17","author":"Samycia","year":"2013","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.coph.2019.04.006_bib0105","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/1744666X.2016.1221762","article-title":"Adalimumab for the treatment of hidradenitis suppurativa\/acne inversa","volume":"12","author":"Zouboulis","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coph.2019.04.006_sbref0110","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"unstructured":"U.S. National Library of Medicine. https:\/\/clinicaltrials.gov.","key":"10.1016\/j.coph.2019.04.006_bib0115"},{"key":"10.1016\/j.coph.2019.04.006_bib0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0125","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.coph.2019.04.006_bib0130","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","article-title":"Successful treatment of severe hidradenitis suppurativa with anakinra","volume":"149","author":"Zarchi","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0140","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2019.04.006_bib0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0150","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2019.04.006_bib0155","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bjd.13292","article-title":"Two cases of severe hidradenitis suppurativa with failure of anakinra therapy","volume":"172","author":"Menis","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000343221","article-title":"Failure of anti\u2013interleukin-1 therapy in severe hidradenitis suppurativa: a case report","volume":"226","author":"van der Zee","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.coph.2019.04.006_bib0165","first-page":"772","article-title":"Failure of anakinra in a case of severe hidradenitis suppurativa","volume":"15","author":"Russo","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0170","first-page":"123","article-title":"Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis","volume":"6","author":"Koutruba","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.coph.2019.04.006_bib0175","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"mAbs"},{"key":"10.1016\/j.coph.2019.04.006_sbref0180","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0185","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa","volume":"26","author":"Gulliver","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2019.04.006_bib0190","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ad.2013.09.011","article-title":"Ustekinumab for hidradenitis suppurativa: a case report","volume":"105","author":"Santos-P\u00e9rez","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.coph.2019.04.006_bib0195","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","article-title":"Successful long-term triple disease control by ustekinumab in a patient with Behcet\u2019s disease, psoriasis and hidradenitis suppurativa","volume":"72","author":"Baerveldt","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2019.04.006_bib0200","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2340\/00015555-1229","article-title":"Management of recalcitrant hidradenitis suppurativa with ustekinumab","volume":"92","author":"Sharon","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2019.04.006_bib0205","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_bib0210","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/bjd.14448","article-title":"Ustekinumab, another biologic with potential to help patients with hidradenitis suppurativa?","volume":"174","author":"Eisen","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_sbref0215","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_sbref0220","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and non-lesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_sbref0225","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/bjd.15769","article-title":"Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_sbref0230","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2340\/00015555-2794","article-title":"Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab","volume":"98","author":"Schuch","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2019.04.006_bib0235","article-title":"Therapeutic response to secukinumab in a 36-year-old woman with hidradenitis suppurativa","volume":"1","author":"J\u00f8rgensen","year":"2018","journal-title":"Case Rep Dermatol Med"},{"key":"10.1016\/j.coph.2019.04.006_bib0240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13543784.2018.1412430","article-title":"Investigational drugs in clinical trials for hidradenitis suppurativa","volume":"27","author":"Riis","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.coph.2019.04.006_sbref0245","first-page":"413","article-title":"Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?","volume":"179","author":"Kanni","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2019.04.006_sbref0250","article-title":"Efficacy and safety of IFX-1, an anti-C5a monoclonal antibody in an open label Phase 2a study in patients with severe hidradenitis suppurativa (HS) not eligible for adalimumab","author":"Giamarellos","year":"2018","journal-title":"Presented at: 7th Conference of the European Hidradenitis Suppurativa Foundation"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489219300098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489219300098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:48:53Z","timestamp":1761461333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489219300098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":50,"alternative-id":["S1471489219300098"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2019.04.006","relation":{},"ISSN":["1471-4892"],"issn-type":[{"type":"print","value":"1471-4892"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological development in hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}